Overactive Bladder News and Research

RSS

Overactive bladder (OAB) is a urological condition defined by a set of symptoms: "urgency, with or without urge incontinence, usually with frequency and nocturia."

QoL questionnaire predicts nocturia, risk for falling

A study of Japanese outpatients highlights the association between nighttime voiding and bone fractures, after showing that the Nocturia Quality-of-Life questionnaire can identify patients at risk for both.

23 Sep 2013

Surgery shows first-line potential for stress urinary incontinence

The authors of a head-to-head study say that surgery should be considered as a first-line option for women with stress urinary incontinence, ahead of physiotherapy.

23 Sep 2013

Overactive bladder leads to underactive patients

Researchers in the USA have shown that patients with overactive bladder experience significant impairment to their physical activity levels.

2 Sep 2013

Targacept reports net loss of $12.4 million for Q2 2013

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today reported its financial results for the second quarter and six months ended June 30, 2013.

6 Aug 2013

Tibial nerve stimulation reduces symptoms of overactive bladder, research finds

Beaumont Health System research finds that symptoms of overactive bladder, or OAB, were reduced in those who received tibial nerve stimulation. The three-year results published in the June issue of The Journal of Urology show participants with urinary frequency, urgency and involuntary loss of urine maintained significant improvement in their symptoms.

31 May 2013

Targacept initiates TC-5214 Phase 2b clinical study in patients with OAB

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of a Phase 2b clinical study of TC-5214 as a treatment for overactive bladder.

29 May 2013

Perrigo receives final approval for generic Sanctura XR

Perrigo Company today announced that it has received final approval for the generic version of Sanctura XR. Perrigo had previously prevailed in litigation at both the district and appellate levels. The product has begun shipping immediately.

29 May 2013

Frutarom reports increased demand for natural ingredient targeting urinary incontinence in adults

Frutarom Health, Switzerland, reports increased demand for Go-Less, its natural ingredient targeting urinary incontinence in adults.

28 May 2013

Uroplasty highlights results of STEP Study on PTNS treatments for overactive bladder

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today highlighted the 3-year results of the STEP Study on percutaneous tibial nerve stimulation treatments for overactive bladder using Uroplasty's Urgent PC Neuromodulation System.

10 May 2013

Targacept reports net loss of $8.1 million in first quarter 2013

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the first quarter ended March 31, 2013.

7 May 2013

USPTO issues Notice of Allowance on Antares Pharma's patent application for VIBEX QS device

Antares Pharma, Inc. announced that it has received a Notice of Allowance from the U.S. Patent Trade Office on a patent application for the VIBEX QuickShot device, the latest advancement in its proprietary line of VIBEX auto-injector systems.

5 Apr 2013

Researchers study specific bacteria that contribute to overactive bladder

Thousands of women suffer from overactive bladder (OAB) or the sudden need to urinate, yet many don't get relief from medication. Researchers at Loyola University Health System believe certain bacteria may be to blame.

4 Apr 2013

First patient dosed in second Phase 2 study with LiRIS for treatment of Interstitial Cystitis

TARIS Biomedical, a specialty pharmaceutical company developing innovative, targeted therapies to treat bladder diseases with high unmet medical need, announced today that it has dosed the first patient in its second Phase 2 clinical study with LiRIS, its novel product candidate, in patients with Interstitial Cystitis.

3 Apr 2013

Previously unknown cell discovered in the urethra of mice

A recent study conducted by a group of German scientists revealed the presence of a previously unknown cell in the urethra of mice. These chemosensory cholinergic brush cells are in close contact to sensory neurons that express cholinergic receptors.

15 Mar 2013

Nationwide survey finds only 13% of women have been diagnosed with OAB symptoms

Today, the National Association for Continence (NAFC) announced findings from a new, nationwide survey of women about overactive bladder (OAB).

14 Mar 2013

Mirabegron reduces frequency of incontinence episodes in phase III trial

In a new phase III trial mirabegron, a β3-adrenoceptor agonist, given once daily for 12 weeks, reduced the frequency of incontinence episodes and number of daily urinations, and improved urgency and nocturia in adults with overactive bladder compared to those in a placebo group.

5 Mar 2013

FDA accepts Antares Pharma's New Drug Application for OTREXUP

Antares Pharma, Inc. today announced that the New Drug Application for OTREXUP, a potential new product for the subcutaneous delivery of methotrexate using Medi-Jet technology, has been accepted by the U.S. Food and Drug Administration indicating that the application is sufficiently complete to permit a substantive review.

27 Feb 2013

Antimuscarinic effective for overactive bladder in elderly

The antimuscarinic drug fesoterodine seems to be an effective and well-tolerated treatment for elderly individuals with an overactive bladder, including those older than 75 years, show findings from a clinical trial.

19 Feb 2013

Targacept reports net loss of $15.9 million for fourth quarter 2012

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today reported its financial results for the fourth quarter and year ended December 31, 2012.

14 Feb 2013

Epithelium able to sense bladder fullness through activity of integrins

If you have an overactive bladder or incontinence, help could be on the way. A new research report published online in the FASEB Journal, shows that the epithelium, a thin layer of cells which line the surface of the bladder, is able to sense how full the bladder is through the action of a family of proteins called integrins.

11 Feb 2013